Clinical Cases & Before/After Data
AURELIA / STEM CELLS

Clinical Cases & Before/After Data

Published individual cases and study cohorts, with administration, follow-up and limitations shown together.

SEE / UNDERSTAND / ASK

Understand the science visually

Open any image at full size. Research pictures, original schematics and generated concepts are labelled separately; none is an Aurelia patient outcome.

Research evidence is not clinical permission — Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.
Principle schematic

Research evidence is not clinical permission

Simplified teaching schematic; cell identity and requirements depend on the actual cell type and intended use.

Original schematic · Aurelia · Scientific reference ↗
Human iPSC colony — Confocal image of an OCA1A research model. OCT4 is red, SSEA4 green and nuclei blue; this is not a treatment result.
Published research image

Human iPSC colony

Confocal image of an OCA1A research model. OCT4 is red, SSEA4 green and nuclei blue; this is not a treatment result.

NIH Image Gallery from Bethesda, Maryland, USA · Public domain
Image source ↗ · Original research / source ↗
Format and display notes

保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。

Neural differentiation in culture — Human embryonic-stem-cell-derived neural progenitors after three weeks of maturation, with morphology and immune markers. Not iPSC or treatment-response images.
Published research image

Neural differentiation in culture

Human embryonic-stem-cell-derived neural progenitors after three weeks of maturation, with morphology and immune markers. Not iPSC or treatment-response images.

Nistor G, Siegenthaler MM, Poirier SN, Rossi S, Poole AJ, Charlton ME, et al. · CC BY 4.0
Image source ↗ · Original research / source ↗
Format and display notes

保留完整画幅和原有标注,仅等比例缩小并转WebP;原始文件同时保留。

How to read the comparison

An individual case is not a trial average. Different diseases, cell products and endpoints cannot be compared as a universal success rate. We redraw published numbers, not patient portraits.

Historical published research, not Aurelia patients or a claim that these treatments are offered here. Individual results and trial means are labelled separately.
01 / Cell 2024 · phase I report · n=1

Type 1 diabetes CiPSC-derived islets

Administration: CiPSC-derived islets transplanted beneath the abdominal rectus sheath; not a routine intravenous infusion.

One patient’s time in target glucose range rose from 43.18% to 96.21% at month 4; the report describes insulin independence from day 75 and follow-up to one year.

Time in target range · higher is better
Baseline: 43.18 %; Month 4: 96.21 %0255075100Baseline43.18%Month 496.21%
View exact data
MeasurementValue
Baseline43.18%
Month 496.21%

Limits and risks

A single uncontrolled case. Previous liver transplantation and existing immunosuppression prevent concluding that autologous cells avoid immune rejection or need no immunosuppression. One year of observation does not establish long-term safety.

ChiCTR2300072200

Cell · DOI 10.1016/j.cell.2024.09.004 ↗

Peking University · original summary ↗

02 / Nature 2025 · open-label phase I/II · efficacy n=6, safety n=7

Parkinson’s disease iPSC dopamine cells

Administration: Bilateral intracerebral putamen transplantation; tacrolimus was used.

Mean MDS-UPDRS III OFF motor score was 50.8 at baseline and 41.3 at 24 months in the six-person efficacy group. These are published table means, not a percentage-based reconstruction.

MDS-UPDRS III OFF · lower is better
Baseline: 50.8 points; Month 24: 41.3 points0336699132Baseline50.8 pointsMonth 2441.3 points
View exact data
MeasurementValue
Baseline50.8 points · SD 14.6
Month 2441.3 points · SD 18.5

Mean (SD), n=6. Full scale 0–132; Extended Data Table 2.

Limits and risks

Small, uncontrolled study. Other endpoints did not consistently improve; the table’s dyskinesia mean increased from 21.0 to 33.3. Absence of serious events in this cohort does not mean zero risk. These trial results are not postoperative data for the 2026 commercial-use patient.

jRCT2090220384

Nature · Extended Data Table 2 ↗

Kyoto University Hospital · trial summary ↗

03 / JAMA 2019 · randomised trial · 110 randomised, 98 assessed at one year

Multiple sclerosis autologous HSCT

Administration: Autologous haematopoietic transplantation after immunosuppressive conditioning; immune reconstitution, not direct nerve regeneration.

At one year, mean EDSS moved from 3.38 to 2.36 with HSCT and from 3.31 to 3.98 with continued disease-modifying therapy. Each arm randomised 55 people.

EDSS · lower is better
HSCT · baseline: 3.38 points; HSCT · year 1: 2.36 points; DMT · baseline: 3.31 points; DMT · year 1: 3.98 points02.557.510HSCT · baseline3.38 pointsHSCT · year 12.36 pointsDMT · baseline3.31 pointsDMT · year 13.98 points
View exact data
MeasurementValue
HSCT · baseline3.38 points
HSCT · year 12.36 points
DMT · baseline3.31 points
DMT · year 13.98 points

Limits and risks

Selected highly active relapsing-remitting MS; not all MS. The regimen includes chemotherapy and immune reconstitution, not direct nerve regeneration. Median follow-up was two years; only 23 had annual five-year evaluation. Infection and conditioning risks remain.

NCT00273364

JAMA · original randomised trial ↗

04 / Lancet 2024 · four-person open-label study; patient 1 shown

Corneal cell sheet a published individual case

Administration: Surgical placement of allogeneic iPSC-derived corneal epithelial sheets.

Patient 1’s corrected distance vision, logMAR, changed from 1.52 before transplantation to 0.52 at week 52. Decimal vision was 0.03 and 0.30 respectively; these are two expressions of the same endpoint.

Patient 1 · logMAR, lower is better
Before transplant: 1.52 ; Week 52: 0.52 00.751.52.253Before transplant1.52Week 520.52
View exact data
MeasurementValue
Before transplant1.52
Week 520.52

One patient, not the mean of all four. Axis 0–3 is the plotted range.

Limits and risks

Four participants, no control. This patient used low-dose ciclosporin and postoperative steroids. Small numbers and limited follow-up cannot establish long-term safety or universal visual recovery.

UMIN000036539

Lancet · DOI 10.1016/S0140-6736(24)01764-1 ↗

PubMed · original study record ↗

05 / FDA · Ryoncil · single-arm study, n=54

MSC intravenous therapy defined paediatric indication

Administration: Intravenous donor bone-marrow MSC product, given under a defined protocol.

At day 28, 16 of 54 participants had complete response and 22 had partial response. This is a response distribution, not a fabricated baseline-to-after measurement.

Day 28 · response counts, n=54
Complete: 16 people; Partial: 22 people; Other: 16 people013.52740.554Complete16 peoplePartial22 peopleOther16 people
View exact data
MeasurementValue
Complete16 people
Partial22 people
Other16 people

Other = 54−16−22, calculated remainder; no baseline response percentage is claimed.

Limits and risks

US approval is for steroid-refractory acute graft-versus-host disease in patients aged at least two months, not general anti-ageing. Infusion reactions and infections are among the risks; this study had no concurrent control.

NCT02336230

FDA · original approval information ↗

FDA · current Ryoncil product information ↗